To the Editor.—
We are most interested in the article by Pettegrew et al1 in this issue of the Archives. The authors report significantly reduced levels of phosphomonoesters (PMEs) and significantly increased levels of phosphodiesters (PDEs) in first-episode, nevertreated schizophrenic patients compared with normal matched control subjects. These findings could indicate decreased synthesis and/or increased breakdown of membrane phospholipids in schizophrenia.We wish to report some preliminary results of localized phosphorus 31 (31P) magnetic resonance (MR) spectroscopy in chronic schizophrenic patients and normal control subjects.
Patients and Methods.—
Ten schizophrenic patients (nine men, one woman) between ages 33 and 54 years (mean± SD, 38.7±6.0 years) participated in the study. All were outpatients receiving an average chlorpromazine hydrochloride equivalent dose of 660 ± 436 mg. The diagnosis of schizophrenia was confirmed by a psychiatrist (P.W.) using the Structured Clinical Interview for DSMIII-R.2 Length of illness was estimated
Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H. Localized Phosphorus 31 Magnetic Resonance Spectroscopy in Chronic Schizophrenic Patients and Normal Controls. Arch Gen Psychiatry. 1991;48(6):578. doi:10.1001/archpsyc.1991.01810300090013
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: